Renalytix Plc (NASDAQ:RNLX) Short Interest Update

Renalytix Plc (NASDAQ:RNLX) was the recipient of a significant growth in short interest in March. As of March 15th, there was short interest totalling 894,600 shares, a growth of 78.7% from the February 29th total of 500,600 shares. Based on an average daily trading volume, of 1,890,000 shares, the short-interest ratio is currently 0.5 days.

Hedge Funds Weigh In On Renalytix

Several large investors have recently modified their holdings of the business. Pinnacle Associates Ltd. raised its position in Renalytix by 7.7% during the 4th quarter. Pinnacle Associates Ltd. now owns 846,534 shares of the company’s stock worth $330,000 after purchasing an additional 60,572 shares during the last quarter. Pentwater Capital Management LP lifted its stake in shares of Renalytix by 5.9% in the third quarter. Pentwater Capital Management LP now owns 598,440 shares of the company’s stock worth $958,000 after acquiring an additional 33,440 shares during the period. Tejara Capital Ltd bought a new stake in Renalytix in the fourth quarter valued at approximately $757,000. Allspring Global Investments Holdings LLC bought a new position in Renalytix during the 3rd quarter worth approximately $547,000. Finally, CI Private Wealth LLC acquired a new position in shares of Renalytix in the 4th quarter worth approximately $352,000. Institutional investors own 9.92% of the company’s stock.

Renalytix Price Performance

Shares of NASDAQ RNLX traded down $0.08 during mid-day trading on Thursday, hitting $0.83. 379,921 shares of the stock traded hands, compared to its average volume of 1,996,581. The company has a market cap of $41.54 million, a PE ratio of -1.82 and a beta of 3.09. Renalytix has a twelve month low of $0.24 and a twelve month high of $4.04. The company has a debt-to-equity ratio of 1.08, a current ratio of 0.59 and a quick ratio of 0.59. The firm has a 50 day simple moving average of $0.75 and a two-hundred day simple moving average of $0.87.

Renalytix (NASDAQ:RNLX) last announced its quarterly earnings results on Wednesday, February 14th. The company reported ($0.09) EPS for the quarter, meeting analysts’ consensus estimates of ($0.09). Renalytix had a negative return on equity of 1,008.88% and a negative net margin of 1,736.47%. The firm had revenue of $0.71 million for the quarter, compared to analyst estimates of $0.70 million.

About Renalytix

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.